SCHEMBL3574589

SCHEMBL3574589

CCC(=O)CC(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7196388 0.85 TDP1 (0.41)
SCHEMBL11639063 0.81 LMNA (0.35)
SCHEMBL11527420 0.78
Chloroform SCHEMBL28140383 0.78 TDP1 (0.71)
SCHEMBL3196745 0.76
SCHEMBL5902723 0.75 TDP1 (0.56)
SCHEMBL17113787 0.73
SCHEMBL12258200 0.73 TDP1 (0.53)
SCHEMBL103502 0.73
Hypochlorous Acid SCHEMBL6139372 0.72 TDP1 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668882-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER Cancer Research Technology Limited (GB) 2020-06-24 EP disclosed
WO-2019034890-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-02-21 WO disclosed
EP-2834234-A1 FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 Janssen Pharmaceutica, N.V. (BE) 2015-02-11 EP disclosed
WO-2013152269-A1 FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA NV (BE) 2013-10-10 WO disclosed
US-7834176-B2 Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E SANDOZ AG (CH) 2010-11-16 US disclosed
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP disclosed
WO-2007087555-A2 NOVEL POLYMORPH 'FORM E ' OF OLANZAPINE (2-METHYL-4- (4-METHYL-1-PIPERAZINYL) -10H-THIENO [2, 3-B] [1, 5] BENZODIAZEPINE) AND PREPARATION OF THE ANHYDROUS NON-SOLVATED CRYSTALLINE POLYMORPHIC 'FORM I' OF OLANZAPINE FROM THE POLYMORPHIC OLANZAPINE 'FORM E' SANDOZ AG (CH) 2007-08-02 WO disclosed
US-20070173496-A1 Novel polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E SANDOZ AG (CH) 2007-07-26 US disclosed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US disclosed
WO-2002038614-A9 CROSSLINKED POLYSACCHARIDE, OBTAINED BY CROSSLINKING WITH SUBSTITUTED POLYETHYLENE GLYCOL, AS SUPERABSORBENT GROUPE LYSAC INC LYSAC GROUP I (CA) 2003-01-23 WO disclosed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US disclosed
US-20020147230-A1 Aminal Diones as potassium channel openers ABBOTT LABORATORIES 2002-10-10 US disclosed
WO-2002038614-A1 CROSSLINKED POLYSACCHARIDE, OBTAINED BY CROSSLINKING WITH SUBSTITUTED POLYETHYLENE GLYCOL, AS SUPERABSORBENT GROUPE LYSAC INC./LYSAC GROUP INC. (CA) 2002-05-16 WO disclosed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US disclosed
US-5874600-A HYDROGENATION OF AN ALKYL 3-OXO-2-ALKYLCYCLOPENTANEACETIC ACID USING A CATALYST OF A RUTHENIUM COMPLEX REACTED WITH A BIDENTATE DIPHOSPHINE LIGAND AND A NONCOORDINATING ACID; STEREOSPECIFIC; PERFUMES; HEDRONE? FIRMENICH SA (CH) 1999-02-23 US disclosed